Home Tags Ovarian cancer

Tag: ovarian cancer

General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer...

The full data and exploratory analyses from the Phase III FORWARD I study (NCT02631876) evaluating mirvetuximab soravtansine, also known as IMGN853, compared to chemotherapy...

Sutro Confirms IND for Second Cell-Free ADC Targeting Anti-Folate Receptor-α for...

Sutro Biopharma confirmed that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for...

Treatment with Siamab ST1 Inhibits Growth of Chemoresistant Ovarian Tumor Cells...

Patients diagnosed with ovarian cancer may have persistent, refractory or recurrent cancer following treatment with surgery and first-line chemotherapy. Generally, persistent cancer refers to...

FORWARD I Phase III Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian...

The FORWARD I Phase III registration trial (NCT02631876) evaluating the antibody-drug conjugate or ADC mirvetuximab soravtansine as a single-agent therapy for the treatment of...

Lifastuzumab Vedotin is Well-tolerated + Improves Objective Response Rate in Phase...

Lifastuzumab vedotin, also known as DNIB0600A (RO5541081) and RG-7599, is an antibody-drug conjugate or ADC.In clinical trials the investigational drug is compared to pegylated...

Data Highlights the Potential to Combine Mirvetuximab Soravtansine with an Immune...

Preclinical data demonstrate the potential for enhancing the activity of mirvetuximab soravtansine, also known as IMGN853, when the investigational agent is combined with and...

XMT-1536 Demonstrates Anti-Cancer Activity in Patients with NaPi2b-expressing Tumors

Preclinical data for Mersana Therapeutics' new immunoconjugate product candidate, XMT-1536, demonstrated significant anti-cancer activity in non-small cell lung cancer (NSCLC) and ovarian cancer tumor models.The...

ImmunoGen and Merck Evaluate Mirvetuximab Soravtansine in Combination with Pembrolizumab in...

ImmunoGen and Merck, known as MSD outside the United States and Canada, have entered into a clinical research collaboration for the assessment of ImmunoGen's...

Compugen’s Antibody Drug Conjugate Program Results Presented

This week, during the World ADC Summit being held October 19 - 22, 2015 in San Diego, CA, Compugen presented the status of its predictive...

Improving Patient Outcomes in Ovarian and Gynecologic Cancers

The University of Texas MD Anderson Cancer Center (Houston, Texas), one of the original three comprehensive cancer centers in the United States established by...